Sodium glucose cotransporter-2-inhibitor dapagliflozin improves nonalcoholic fatty liver disease by ameliorating dipeptidyl-peptidase-4 protein expression in diabetic mice.

Dong-Ming Zhao,Cheng-Qiang Li,Yu-Man Sun,Jin-Yang Fan,Nan Wu,Ya-Nan Sun,Xin-Yi Sun

Endokrynologia Polska（2023）

引用 1|浏览1

暂无评分

摘要

Dapagliflozin may be an effective drug for the treatment of T2DM-induced NAFLD and NAFLD, providing a reliable laboratory basis and new treatment methods for the clinical treatment of NAFLD.

查看译文

关键词

dapagliflozin,dipeptidyl-peptidase 4,nonalcoholic fatty liver disease,sodium glucose cotransporter-2 inhibitor,type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要